The Shanghai Key Laboratory of Hypertension, formerly known as "Shanghai Key Laboratory of Vascular Biology", was established by Professor ZHU Dingliang in May 1999 with the support of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine and Shanghai Institute of Hypertension and renamed "Shanghai Key Laboratory of Hypertension" in July 2012. The current director of the lab is Professor GAO Pingjin.The lab seeks to incorporate both clinical and basic studies of hypertension to explore novel developments and establish new models for hypertension research. Expanding upon prior work involving the molecular mechanism of hypertensive vascular remodeling and perivascular homeostasis in particular, the lab has been focused on investigating new targets for inflammatory and immune mediators regulating blood pressure in recent years. In addition, a clinical problem-oriented hypertension study cohort was established to validate and predict the biomarkers leading to the risk of hypertension. The lab has upheld the overall development goal of "blood pressure regulation - target organ damage - clinical transformation" and has continuously explored new mechanisms and targets for intervention of hypertension, as well as the research and development of various new technologies and translational scientific research, and has achieved original achievements of important scientific value. For example, new target sites of hypertension unique to East Asian populations have been discovered in collaboration with international colleagues. New subtypes of hypertension were further analyzed and a unique treatment scheme for masked hypertension was explored. In recent years, we discovered new inflammatory and immune mechanisms of blood pressure regulation and identified novel intervention targets for target organ damage. A series of study results have been published in international academic journals such as Nature Genetics, Cell Metabolism, Circulation, Circulation Research, and Journal of Experimental Medicine. As chairman of the Chinese Hypertension League, Professor WANG Jiguang actively led the update of Chinese hypertension guidelines and blood pressure monitoring guidelines, etc. He currently serves as the editor-in-chief for the Journal of Clinical Hypertension and associate editor for Hypertension. Professor GAO Pingjin is an editor at Cardiovascular Research and a guest editor at Hypertension. The lab has trained New Century Excellent Talents of the Ministry of Education, Outstanding Youth of the National Natural Science Foundation, Excellent Academic Leader Plan of Shanghai, etc. The lab has undertaken a number of National Natural Science Foundation of China key projects and major research projects; moreover, it has established substantial cooperative relations with famous cardiovascular professional institutions in multiple countries.

http://www.rjh.com.cn/2018RJPortal/gxyyjs/shsgxyzdsys/index.shtml